JPMorgan raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $77 from $53 and keeps an Overweight rating on the shares. The firm “meaningfully” increased its Livmarli forecasts following the company’s “strong” Q2 beat. With potentially registrational data for volixibat in primary sclerosing cholangitis in Q2 of 2026, Mirum shares have further upside should the trial prove successful, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals completes enrollment in VISTAS study of volixibat
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment
- Mirum Pharmaceuticals files automatic mixed securities shelf
- Arm initiated, Adobe downgraded: Wall Street’s top analyst calls